Announcements Trials

Browse Landscape

Phase

Status

Completed 6 Terminated 5 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 184 Carboplatin 132 Cisplatin 102 Paclitaxel 101 Gemcitabine 86 Pemetrexed 79 durvalumab 75 Nivolumab 67 Docetaxel 55 atezolizumab 51 Cyclophosphamide 49 Bevacizumab 49 Dexamethasone 45 Capecitabine 45 Oxaliplatin 42 130-nm albumin-bound paclitaxel 41 Rituximab 40 Fulvestrant 39 Lenalidomide 38 Fluorouracil 37 Prednisone 32 osimertinib 31 olaparib 29 venetoclax 28 fludarabine 28 Leucovorin 28 Trastuzumab 27 Doxorubicin 27 Etoposide 25 Cetuximab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × INDUSTRY × RRx-001 × Clear all

NCT05566041 2024-10-31

REPLATINUM

EpicentRx, Inc.

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡